X-ray powder diffraction in solid form screening and selection

American Pharmaceutical Review

Volumn 14, Issue 6, 2011, Pages 44-51

  Newman, Ann ^a  

^a Seventh Street Development Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHLORIDE;

DISPERSION; MASS SPECTROMETRY; REVIEW; SCREENING; SOLID STATE; X RAY POWDER DIFFRACTION;

EID: 80054963924     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. G. P. Stahly, "Diversity in Single- and Multiple-Component Crystals. The Search for and Prevalence of Polymorphs and Co-crystals", Crystal Growth and Design, 2007, 7, 1007-1026.
2. S.Bassavoju, S. Bostrom, S. P. Velaga, "Pharmaceutical Co-crystal and Salts of Norfloxacin", Crystal Growth and Design, 2006, 6, 2699-2708.
3. D. Engers, J. Teng, J. Jimenex-Novoa, P. Gent, S. Hossack, C. Campbell, J. Thomson, I. Ivanisevic, A. Templeton, S. Byrn, A. Newman, "A Solid-State Approach to Enable Early Development Compounds: Selection and Animal Bioavailability Studies of an Itraconazole Amorphous Solid Dispersion", Journal of Pharmaceutical Sciences, 2010, 99, 3901-3922.
4. L. M. Katrincic, Y. T. Sun, R. A. Carlton, A. N. Diederich, R. L. Mueller, F. G. Vogt, "Characterization, Selection, and Development of an Orally Dosed Drug Polymorph from an Enantiotropically Related System", International Journal of Pharmaceutics, 2009, 366, 1-13.
5. Polymorphism in the Pharmaceutical Industry, Edited by R. Hilfiker, Wiley-VCH, Weinheim, 2006.
6. A. W. Newman, S. L. Childs, B. A. Cowans, "Salt and Co-crystal Form Selection" in Preclinical Development Handbook, John Wiley and Sons, Hoboken, 2008, 455-481.
7. S.L. Childs, L.J. Chyall, J. T. Dunlap, V. N. Smolenskaya, B.C. Stahly, G.P. Stahly, "Crystal Engineering Approach to Forming Co-crystals of Amine Hydrochlorides with Organic Acids. Molecular Complexes of Fluoxetine Hydrochloride with Benzoic, Succinic, and Fumaric Acids", Journal of the American Chemical Society, 2004, 126, 13335-13342. (Pubitemid 39382761)
8. B.E. Padden, J.M. Miller, T. Robbins, P.D. Zocharski, L. Prasad, J.K. Spence, J. LaFountaine, "Amorphous Solid Dispersions as Enabling Formulations for Discovery and Early Development", American Pharmaceutical Review, 2011, Jan/Feb, 66-73.
9. (a) M.S. Nagarsenker, R.N. Meshram, G. Ramprakash, "Solid Dispersion of Hydroxyopropyl-cyclodextrin and Ketorolac: Enhancement of In-vitro Dissolution Rates, Improvement in Anti-inflammatory Activity and Reduction in Ulcerogenicity in Rats", Journal of Pharmacy and Pharmacology, 2000, 52, 949-956.
10. (b) M. Fuji, K. Harada, M. Matsumoto, "Physicochemical Properties of Phenobarbital Solid Dispersions with Phosphatidylcholine", Chemistry and Pharmaceutical Bulletin, 1990, 38, 2237-2241. (Pubitemid 20338188)
11. XRPD pharma ref. H.B. Brittain, "X-Ray Powder Diff raction of Pharmaceutical Materials", American Pharmaceutical Review, 2002, 5, 74-80.
12. (a) M.K. Stanton, R.C. Kelly, A. Colletti, Y.-H. Kiang, M. Langley, E.J. Munson, M.L. Peterson, J. Roberts, M. Wells, "Improved Pharmacokinetics of AMG 517 Through Co-Crystallization Part 1: Comparison of Two Acids with Corresponding Amide Co-Crystals", Journal of Pharmaceutical Sciences, 2010, 99, 3769-3778.
13. (b) M. Kennedy, . Hu, P. Gao, L. Li, A. Ali-Reynolds, B. Chal, V. Gupta, C. Ma, N. Mahajan, A. Akrami, S. Surapaneni, "Enhanced Bioavailability of a Poorly Soluble VR1 Antagonist Using an Amorphous Solid Dispersion Approach: A Case Study", Molecular Pharmaceutics, 2008, 5, 981-993.
14. C. Anderton, "A Valuable Technique for Polymorph Screening", American Pharmaceutical Review 2007, March/April, 34-40.
15. J.M. Miller, B.M. Collman, L.R. Greene, D.J.W. Grant, A.C. Blackburn, "Identifying the Stable Polymorph Early in the Drug Discovery-Development Process", Pharmaceutical Development and Technology, 2005, 10, 291-297. (Pubitemid 40677449)
16. J. Aaltonen, M. Alleso, S. Mirza, V. Koradia, K.C. Gordon, J. Rantanen, "Solid Form Screening - A Review", European Journal of Pharmaceutics and Biopharmaceutics, 2009, 23-37.
17. R. Storey, R. Docherty, P. Higginson, C. Dallman, C. Gilmore, G. Barr, W. Dong, "Automation of Solid Form Screening Procedures in the Pharmaceutical Industry - How to Avoid the Bottlenecks", Crystallography Reviews, 2004, 10, 45-56. (Pubitemid 40026209)
18. A. Newman, D. Engers, S. Bates, I. Ivanisevic, R. C. Kelly, G. Zografi, "Characterization of API : Polymer Mixtures Using X-ray Powder Diff raction", Journal of Pharmaceutical Science, 2008, 97(11), 4840-4856.
19. K.R. Morris, U.J. Griesser, C.J. Eckhardt, J.G. Stowell, "Theoretical Approaches to Physical Transformations of Active Pharmaceutical Ingredients during Manufacturing Processes", Advanced Drug Delivery Reviews, 2001, 48, 91-114. (Pubitemid 32452293)
20. (a) M. Pudipeddi, A.T.M. Serajuddin, "Trends in Solubility of Polymorphs", Journal of Pharmaceutical Sciences, 2005, 94, 929-939.
21. Hancock and Parks, "What is the True Solubility Advantage for Amorphous Pharmaceuticals?", Pharmaceutical Research, 2000, 17, 397-404.
22. L.X. Yu, "Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control", Pharmaceutical Research, 2008, 25, 781-791.
23. S. R. Byrn, R. R. Pfeiff er, and J. G. Stowell, Solid-State Chemistry of Drugs, 2nd edition, SSCI, Inc, West Lafayette, IN 1999.
24. S.X. Yin and J.A. Grosso, "Selecting and Controlling API Crystal Form for Pharmaceutical Development-Strategies and Processes", Current Opinion in Drug Discovery and Development, 2008, 11, 771-777.
25. G. Z. Zhang, D. Law, E.A. Schmitt, Y. Qiu, "Phase Transformation Considerations during Process Development And Manufacture of Solid Oral Dosage Forms", Advanced Drug Delivery Review, 2004, 56, 371-390. (Pubitemid 38202329)